Vaccine stocks gain amid uptick in flu, COVID-19, RSV
Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in ...
Covid-19 spike proteins linger in the brain for years: Study
Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, ...
Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
WESA10h
Penn expecting $467M windfall from COVID-19 vaccine royalty dispute
The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...
Niagara Gazette11h
5 things we know and still don't know about COVID, 5 years after it appeared
Five years ago, a cluster of people in Wuhan, China, fell sick with a virus never before seen in the world. The germ didn't ...
Long COVID Breakthrough: Spike Proteins Persist in Brain for Years
Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...
Deutsche Bank Sticks to Their Buy Rating for Novo Nordisk (0QIU)
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Pharmaceutical Technology18h
BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Pharmaceutical Technology19h
Trastuzumab pamirtecan by BioNTech for Solid Tumor: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...